MNCs Applaud Shanghai Zhangjiang Hi-tech Park Pilot Program To Accelerate Biomaterial Imports
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Ten research centers in Shanghai Zhangjiang Hi-tech Park have passed inspections by the General Administration of Quality Supervision, Inspection and Quarantine for the first round of a pilot program aimed at simplifying import procedures and at shortening the time it takes to approve imported biomaterial
You may also be interested in...
BIO Welcomes First Chinese Members: Shanghai Zhangjiang Park And Taizhou Medical City
SHANGHAI - BIO, the largest biotechnology organization with 1,200 members around the world, announced its first two members from China - Zhangjiang Hi-tech Park in Shanghai and China Medical City in Taizhou - during the group's annual convention in Chicago
BIO Welcomes First Chinese Members: Shanghai Zhangjiang Park And Taizhou Medical City
SHANGHAI - BIO, the largest biotechnology organization with 1,200 members around the world, announced its first two members from China - Zhangjiang Hi-tech Park in Shanghai and China Medical City in Taizhou - during the group's annual convention in Chicago
Shanghai Hi-Tech Park Acquires Stake In Medical Devices Company MicroPort As Part Of Overhaul Of Shanghai Pharmaceutical Industry
SHANGHAI - Shanghai Zhangjiang Hi-Tech Park Development announced June 27 the company will pay $85.35 million to acquire a 24.4 percent stake in MicroPort Scientific